en
Scientific article
Open access
English

Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials

Published inRMD Open, vol. 3, no. 2, e000496
Publication date2017
Abstract

Two randomised controlled trials, AMBITION (NCT00109408) and ADACTA (NCT01119859), showed tocilizumab (TCZ) monotherapy superior to methotrexate (MTX) and adalimumab (ADA) monotherapy, respectively, for improving rheumatoid arthritis (RA) disease activity. This study compared the benefit of TCZ versus MTX or ADA monotherapy for improving patient-reported outcomes (PROs) in patients with RA.

Citation (ISO format)
STRAND, Vibeke et al. Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials. In: RMD Open, 2017, vol. 3, n° 2, p. e000496. doi: 10.1136/rmdopen-2017-000496
Main files (1)
Article (Published version)
Identifiers
ISSN of the journal2056-5933
337views
206downloads

Technical informations

Creation09/03/2018 11:20:00 AM
First validation09/03/2018 11:20:00 AM
Update time03/15/2023 1:12:01 PM
Status update03/15/2023 1:12:00 PM
Last indexation02/12/2024 12:56:18 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack